Claims

[1. A method of inhibiting fungal growth in a host comprising administering to a host infected with a fungi, a composition comprising an acceptable carrier and a compound selected from the group consisting of formulae 1a, 1b, 1c, 1d and 1e, for a time and under conditions effective to inhibit fungal growth wherein the structures of said formulae are as follows:



1a, Dolastatin 10
(Dov-Val-Dil-Dap-Doe)



1b, Dov-Val-Dil-Dap-Phe-3-[(5-phenyl)-1,4-thiadiazolamide]



1c, Dov-Val-Dil-Dap-Phe-3-[(5-thiomethyl)-1,4-thiadiazolamide]



1d, Dov-Val-Dil-Dap-Phe-OMe



1e, Dov-Val-Dil-Dap-Met-3-quinolylamide

2. The method according to claim 1 in which said fungal growth is *Cryptococcus neoformans*.

3. The method according to claim 1 in which said fungal growth are cryptococcosis and epidermal and systemic infections resulting from contact with *Cryptococcus neoformans*.]

4. The method according to claim 9 in which said [active ingredient] <u>composition</u> is administered to said [host] <u>mammal</u> by parenteral means.

5. The method according to claim 9 in which said [active ingredient] composition is administered topically to said [host] mammal.

6. The method according to claim 9 in which said [active ingredient] composition is administered intravenously to said [host] mammal.

7. The method according to claim 9 in which said [active ingredient] composition is administered in a suppository inserted in said [host] mammal.

8. The method according to claim 5 wherein [said carrier] said carrier is selected from the group consisting of a water-and-oil emulsion, petrolatum, mineral oil, a moisturizer, and a solubilizer.

9. The method according to claim [3] 19 wherein said host is a mammal.

10. The method according to claim 9 in which said mammal is a human.

11. The method according to claim 10 in which said [active ingredient] composition is administered to said [host] human by parenteral means.

12. The method according to claim 10 in which said [active ingredient] composition is administered topically to said [host] human.

13. The method according to claim 10 in which said [active ingredient] composition is administered intravenously to said [host] human.

14. The method according to claim 10 in which said active ingredient is

administered in a suppository inserted in said host.

15. The method according to claim 12 wherein [said carrier] said carrier is selected from the group consisting of a water-and-oil emulsion, petrolatum, mineral oil, a moisturizer, and a solubilizer.

16. A method of inhibiting growth of a fungus in a host that is infected with a fungus comprising administering to said host a composition comprising an acceptable carrier, and a compound selected from the group consisting of formulae 1a, 1b, 1c, 1d, and 1e, wherein said method, said composition is administered to the host for a time and under conditions effective to inhibit [said fungal growth] growth of said fungus; and wherein the structures of said formulae are as follows:



1a, Dolastatin 10
(Dov-Val-Dil-Dap-Doe)



1b, Dov-Val-Dil-Dap-Phe-3-[(5-phenyl)-1,4-thiadiazolamide]



1c, Dov-Val-Dil-Dap-Phe-3-[(5-thiomethyl)-1,4-thiadiazolamide]



1d, Dov-Val-Dil-Dap-Phe-OMe



1e, Dov-Val-Dil-Dap-Met-3-quinolylamide

17. The method of claim 8 in which said carrier contains a fragrance.

18. The method of claim 15 in which said carrier contains a fragrance.

19. The method according to claim 16 wherein said fungus is *Cryptococcus neoformans*.

20. The method according to claim 9 wherein said mammal is infected

systematically with *Cryptococcus neoformans*.

21. The method according to claim 9 wherein the epidermis of said mammal is infected with *Cryptococcus neoformans*.

Claims

4. The method according to claim 9 in which said composition is administered to said mammal by parenteral means.

5. The method according to claim 9 in which said composition is administered topically to said mammal.

6. The method according to claim 9 in which said composition is administered intravenously to said mammal.

7. The method according to claim 9 in which said composition is administered in a suppository inserted in said mammal.

8. The method according to claim 5 wherein said carrier is selected from the group consisting of a water-and-oil emulsion, petrolatum, mineral oil, a moisturizer, and a solubilizer.

9. The method according to claim 19 wherein said host is a mammal.

10. The method according to claim 9 in which said mammal is a human.

11. The method according to claim 10 in which said composition is administered to said human by parenteral means.

12. The method according to claim 10 in which said composition is administered topically to said human.